


# Cost-Effective Products for the Detection and Diagnosis of Cancer and Cancer-Related Diseases




**CytoCore inc.**  
*core solutions for innovative care.*

# Forward-looking statement

- This presentation contains forward-looking information. These forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be significantly impacted by certain risks and uncertainties described herein and in the Company's Annual Report on Form 10-KSB for the year ended December 31, 2008, filed with the Securities and Exchange Commission.

# Our Approach

## CytoCore Solutions™



•From collection to treatment, CytoCore's technologies improve processes and results.

- Radically enhanced accuracy
- Reduced the time per result
- Improved patient outcomes
- Reduced burden to healthcare's financial systems

# CytoCore Focus

- CytoCore has developed a suite of technologies, for use individually or as a unified solution, to detect precancerous (dysplasia) and cancerous lesions, and to treat dysplasia.

# Key CytoCore Products

- Improved Sample Collection (SoftPAP)
  - Reduced false positives and negatives
- Improved Specimen Preparation (Preservative)
  - For both manual and automated processing
- Improved Specimen Staining (C1, T1, H1, H2)
  - Shorter cycle time, Proprietary diagnostic tests
- Improved Specimen Screening (AIPS)
  - Computer Assisted Cytology/Location Guided Screening
- Improved Data Management (AIPS, DMS)
  - Integrated specimen, regulatory & operational data capture & management
- Improved Communications (OmniDROP)
  - Secure HIPAA-compliant between Lab <-> Physician <-> Patient <-> Suppliers

# Plans presented in 2008

- SoftPAP sales through distributors in Europe
- Signed contracts in place with 3 distributors
- Begin full scale selling as soon as clinical trial data became available
- Direct sales force in US – target premium market early adopters
- AIPS workstation, AIPS Imager and Assay development continued from cash generated from SoftPAP sales
- PadKit Launch
- OmniDrop Launch

# Since then...

- Europe
  - Sales delayed:
    - Final clinical trials data not released until late November 2008
    - Expected publication of data in International Journal of Obstetrics and Gynecology in process
    - Sales strategy modified to include SoftPAP collector with preservative for making monolayer slides
      - 80% of US, 20% of EU and <5% of rest of the world market is now monolayer
      - Current methods require expensive slide preparation equipment, consumables and a cyto-technician's assistance
      - This is not financially feasible for labs that predominate outside of US

# Since then...

- **US Sales**
  - Due to current economic conditions, physicians were hesitant to collect an additional fee for SoftPAP
  - However, survey results revealed that 86.8% women would be willing to pay an additional ten to twenty dollars for a more accurate Pap test
  - SoftPAP “kit” is expected to be an insurance reimbursable product
- **AIPS and Assays**
  - Concentrating on in-house firmware and software
  - Continuing assay development
- **PadKit and OmniDrop**
  - Padkit launch deferred to conserve cash
  - OmniDrop launch delayed by developer

# Trial Results

This trial was conducted at seven sites within the continental US. The same IRB protocol was followed at all sites. The objective of the trial was to assess the adequacy, efficacy, and safety between the *SoftPAP*<sup>TM</sup> cervical cell collector and the standard Cytobrush/Spatula technique. Analysis from 703 data samples follow.

Adequacy of Cells for Diagnosis	
	% Satisfactory/Not Limited
<i>SoftPAP</i> <sup>TM</sup> Totals	98.6 %
Brush Totals	99.2 %

Efficacy (2 of 3 consensus)		
	False Positives	False Negatives
<i>SoftPAP</i> <sup>TM</sup> -All Slides	15.6%	7.3%
Brush – All Slides	22.9%	9.9%
Reduction - <i>SoftPAP</i> <sup>TM</sup> vs. Brush	33%	26%

\*\* Sensitivity (the ability to detect abnormal cells) for *SoftPAP*<sup>TM</sup> was 89.7% vs. 86.3% for Brush/Spatula

\*\* Results show a lower number of endocervical cells, but a higher number of metaplastic cells collected by the *SoftPAP*<sup>TM</sup>

# Current Strategies and Progress

- SoftPAP
  - Formal final data released in November 2008
    - Data submitted for publication on [www.clinicaltrials.gov](http://www.clinicaltrials.gov)
  - Formal paper drafted
    - Under final review by Principal Investigators
    - Expect to publish in International Journal of Gynecology and Obstetrics
  - Packaging:
    - Kit SoftPAP® with a cytological preservative for sale to physicians as a single product.
    - Price this kit at parity with competing kits
  - Distribution:
    - In the US: partner with a national medical products distributor that reaches both the physician and lab markets and which has affiliations or operations Internationally.
    - International: partner with national or regional distributors (preferably affiliates of the US distributor) as appropriate

# SoftPAP Marketing Plan

- Integrated approach to both physicians and labs in target areas in the US
  - Focus on early adopters who want innovative technology
  - Supported by:
    - Dedicated SoftPAP® website
    - Viral marketing campaign
    - Work with health-focused women's groups and events
    - Digital media marketing
    - Testimonials
- Approach varies by country internationally - primarily through distributor sales force
  - Lab-centric in countries such as Germany where the labs largely control which products are used by physicians
  - Physician-centric in countries where physicians do their own lab work or where there is a strong private health care sector operating in parallel with a socialized health care system.
  - Work with the appropriate National Healthcare Authorities in countries where healthcare is predominantly socialized


# SoftPAP Marketing Plan

- **Distribution Agreement with Amsino**
  - Worldwide
  - Working with sub-distributors
  - Includes entering US market through an Amsino sub-distributor
- **Status of current European distribution agreements**
- **Preservative agreement with Synermed**
  - Worldwide collaboration using Amsino and Synermed distribution channels
  - Preparing for International launch of SoftPAP and preservative kits
  - Addressing regulatory issues for kits in US
  - Option to add slide preparation instrument
  - Kit addresses objections raised by European Distributors
    - Can make slides manually at rate competitive with instruments
    - Low cost consumables
    - Medium and high throughput instruments available for larger labs

## Other launches and Equity

- **PadKit and Omnidrop**
  - Arrangements made to validate PadKit with Synermed preservative as part of UCLA trial
  - OmniDrop beta release now expected Q3 of 2009
- **Use of proceeds from equity raise**
  - AIPS workstation beta units
  - Clinical trials for preservative to be used for cervical cytology

# Commercialization Timeline



# Future events

- SoftPAP kit launch through distributors in US, China, South America and Europe
- Trials and submissions for SoftPAP and Preservative kits in US initiated
- SoftPAP trial paper published
- Equity raise
- AIPS workstation beta hardware in field tests
- AIPS assays ready for trials